Immunopathology & Immunotherapy

Including Immunology (pathology and therapies) topics:

• 29 TYpE 2 DiAbETES MElliTUS | A central role of the gut in glucose homeostasis; Geltrude Mingrone and Lidia Castagneto-Gissey
• 30 METAbOliSM | The gut microbiota manages host metabolism; Patrice D. Cani
• 35 hEpATiTiS C | HCV causes systemic disorders that can be cured; Francesco Negro
• 37 fAECAl MiCRObiOTA TRANSplANTATiON | Developing human gut microbiota as a class of therapeutics; Alexander Khoruts
• 38 COEliAC DiSEASE | New insights in dietary-gluten-induced autoimmunity; Katri Kaukinen and Markku Mäki
• 42 ibD | Enriching the therapeutic armamentarium for IBD;  Silvio Danese and Laurent Peyrin-Biroulet
• 51 TRANSplANTATiON iMMUNOlOgY | New approaches to diagnosis of rejection; Nicholas A. Zwang and Laurence A. Turka
• 65 MUlTiplE SClEROSiS | Novel triggers, treatment targets and brain atrophy measures; Xavier Montalban and Mar Tintoré
• 71 SYSTEMiC lUpUS ERYThEMATOSUS | Taking a closer look at biologic therapy for SLE; David A. Isenberg and Anisur Rahman
• 72 EpigENETiCS | DNA methylation and miRNA—key roles in systemic autoimmunity; Bruce C. Richardson and Dipak R. Patel
• 74 RhEUMATOiD ARThRiTiS | Translational medicine in RA—time for change; Pierre Miossec

Theofilopoulos and Baccala are confident that SLC15A4 is a potential target for a new SLE therapy. A drug that would target SLC15A4 could potentially suppress only the immune cells directly responsible for SLE, without affecting the rest of the immune system. The research team is currently trying to develop a new pharmacological compound capable of inhibiting the production of type 1 interferon. This inhibition would be possible if the expression of the SLC15A4 gene could be blocked.